Table 1 Inclusion and Exclusion criteria.

From: Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial

Inclusion criteria

Exclusion criteria

Patients aged 18–75 years

VKA treatment within 7 days before enrollment or other indication for VKA

IFDVT objectively confirmed by imaging of computed tomography or duplex ultrasound

Creatinine clearance <30 mL/min

The onset of symptoms within the past 21 days

Clinically significant liver disease (e.g., acute hepatitis, chronic active hepatitis, or cirrhosis)

Successful catheter-directed thrombolysisa

Liver enzyme level >3X the upper limit of the normal range

Informed consent

Bacterial endocarditis

 

Active bleeding or a high risk of bleeding

 

Contraindications to anticoagulation

 

Systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg

 

Childbearing potential without proper contraceptive measures, pregnancy, or breastfeeding

 

Malignant disease needing chemotherapy

  1. Note: aSuccessful catheter-directed thrombolysis was defined as complete resolution of the thrombus or a residual thrombosis less than 50% without flow disturbance.
Back to article page